COVID-19 Protection After Transplant Pilot Study (CPAT)

National Institute of Allergy and Infectious Diseases (NIAID) logo

National Institute of Allergy and Infectious Diseases (NIAID)

Status and phase

Completed
Phase 2

Conditions

Kidney Transplant Recipients

Treatments

Biological: mRNA-1273 vaccine (Moderna)
Biological: mRNA-1273 vaccine (Pfizer/BioNTech)

Study type

Interventional

Funder types

Industry
NIH

Identifiers

NCT04969263
DAIT COVID19-TB-02
NIAID CRMS ID#: 38865 (Other Identifier)

Details and patient eligibility

About

Antibodies are an important part of the body's defense against infection. Individuals who have no antibodies or very low antibody levels are considered less well protected from Coronavirus Disease 2019 (COVID-19) than those who have higher antibody levels. What level of antibodies is necessary for protection is currently unknown. Inadequate antibody response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccination has been described among kidney transplant recipients. The aim of this study is to elicit an antibody response to vaccination against SARS-CoV-2 in kidney transplant recipients who have failed to respond to two doses of either the Moderna COVID-19 vaccine or Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) vaccine.

Full description

This is an open label, non-randomized study in kidney transplant recipients who received two doses of either mRNA COVID-19 vaccine and have a negative (<0.8 U/mL) or low (titer <50 U/mL) SARS-CoV-2 antibody response using the Roche Elecsys® anti-RBD assay. Eligible participants will receive a third dose of the same mRNA vaccine as the prior two doses.

Enrollment

81 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Individuals who meet all the following criteria are eligible for enrollment as study participants-

  • Able to understand and provide informed consent;
  • Recipient of kidney transplant ≥12 months prior to enrollment, without treated allograft rejection in the 6 months preceding enrollment;
  • Received 2 doses of either the Moderna COVID-19 vaccine or Pfizer-BioNTech COVID-19 vaccine as specified in the respective Food and Drug Administration Emergency Use Authorization (FDA EUAs), >30 days and <8 months prior to enrollment ; and,
  • Negative (antibody titer < 0.8U/mL) or low (antibodies detected at titer ≤ 50 U/mL) response to the vaccine at > 30 days from dose 2 of the Moderna COVID-19 vaccine or the Pfizer BioNTech vaccine, using the Roche Elecsys® anti-Receptor Binding Domain (RBD) assay.

Exclusion criteria

Individuals who meet any of these criteria are not eligible for enrollment as study participants-

  • Recipient of any number of doses of any COVID vaccine product other than the Moderna COVID-19 vaccine or the Pfizer-BioNTech COVID-19 vaccine;
  • Known history of severe allergic reaction to any component of either the Moderna COVID-19 vaccine or Pfizer-BioNTech COVID-19 vaccine;
  • Thrombotic events, myocarditis, or pericarditis temporally associated with prior dose of COVID-19 vaccine;
  • Any change in transplant immunosuppression regimen (drug or dose) in response to suspected or proven rejection within the last 6 months;
  • Significant graft dysfunction;
  • Receipt of any cellular depleting agent (e.g. ATG, Rituximab, Alemtuzumab, Cyclophosphamide) within 12 months preceding enrollment;
  • Receiving systemic immunomodulatory medication(s) for any condition other than transplant;
  • Any untreated active infection, including BK viremia >10^4 copies;
  • Infection with human immunodeficiency virus (HIV);
  • Maintenance immunosuppressive regimen that includes belatacept or abatacept;
  • Recent (within one year) or ongoing treatment for malignancy; or
  • Any past or current medical problems, treatments, or findings which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the candidate's ability to comply with study requirements or may impact the quality or interpretation of the data obtained from the study.

Trial design

81 participants in 2 patient groups

mRNA-1273 vaccine (Pfizer/BioNTech)
Experimental group
Description:
The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Pfizer/BioNTech will receive a third dose of the the same vaccine. Administration: One dose administered intramuscularly, upper arm.
Treatment:
Biological: mRNA-1273 vaccine (Pfizer/BioNTech)
mRNA-1273 vaccine (Moderna)
Experimental group
Description:
The mRNA-1273 vaccine was developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. Kidney transplant recipients who had a suboptimal antibody response to the standard two doses of vaccination with Moderna will receive a third dose of the same vaccine. Administration: One dose administered intramuscularly, upper arm.
Treatment:
Biological: mRNA-1273 vaccine (Moderna)

Trial documents
1

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems